Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.74 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.74 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.74 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.74 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.74 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.74 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.74 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.74 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.74 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.74 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.74 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4745983 | 0.92 | CHRM2 (0.71) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL15510714 | 0.87 | CHRM2 (0.82) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| SCHEMBL709359 | 0.86 | CHRM2 (0.80) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| SCHEMBL19129074 | 0.86 | TMEM97 (0.80) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL8170 | 0.85 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL8623049 | 0.85 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL6746375 | 0.85 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL9047 | 0.85 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL31023589 | 0.85 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| SCHEMBL1695848 | 0.85 | CHRM2 (0.78) | CHRM2CHRM4CHRM5ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048135-A1 | COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | Atrium Therapeutics, Inc. | 2026-02-19 | — | — | US | disclosed |
| US-12529056-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20260014266-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | AVIDITY BIOSCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260007766-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2026-01-08 | — | — | US | disclosed |
| US-20250381285-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | AVIDITY BIOSCIENCES INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250381286-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | AVIDITY BIOSCIENCES INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12491257-B2 | Compositions and methods of using PRKAG2-targeting antibody-oligonucleotide conjugates | AVIDITY BIOSCIENCES, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4656242-A2 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | Avidity Biosciences, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12486328-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250352651-A1 | COMPOSITIONS COMPRISING PLN-TARGETING ANTI-TRANSFERRIN RECEPTOR ANTIBODY-POLYNUCLEOTIDES AND METHODS OF USE THEREOF TO TREAT CARDIOMYOPATHY | Atrium Therapeutics, Inc. | 2025-11-20 | — | — | US | disclosed |
| US-9687557-B2 | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates | ONXEO (FR) | 2017-06-27 | — | — | US | disclosed |
| EP-3135301-A1 | OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES | DNA Therapeutics (FR) | 2017-03-01 | — | — | EP | disclosed |
| US-20160339107-A1 | OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES | VALERIO THERAPEUTICS (FR) | 2016-11-24 | — | — | US | disclosed |
| US-9428538-B2 | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates | DNA THERAPEUTICS (FR) | 2016-08-30 | — | — | US | disclosed |
| US-20160046662-A1 | OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES | VALERIO THERAPEUTICS (FR) | 2016-02-18 | — | — | US | disclosed |
| US-9205101-B2 | Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia | INSTITUT CURIE (FR) | 2015-12-08 | — | — | US | disclosed |
| US-9205099-B2 | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates | DNA THERAPEUTICS (FR) | 2015-12-08 | — | — | US | disclosed |
| US-20140100266-A1 | CANCER TREATMENT BY COMBINING DNA MOLECULES MIMICKING DOUBLE STRAND BREAKS WITH HYPERTHERMIA | DNA THERAPEUTICS (FR) | 2014-04-10 | — | — | US | disclosed |
| US-20130131155-A1 | Optimized In Vivo Delivery System with Endosomolytic Agents for Nucleic Acid Conjugates | DNA THERAPEUTICS (FR) | 2013-05-23 | — | — | US | disclosed |
| US-20040229908-A1 | Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias | Greenlee, Winner and Sullivan, P.C. | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140100266-A1 | CANCER TREATMENT BY COMBINING DNA MOLECULES MIMICKING DOUBLE STRAND BREAKS WITH HYPERTHERMIA | MRE11, TOP2A, DNASE1L3 | CHRM2 4874/4885CHRM4 4845/4885CHRM5 4864/4885 |
| US-20250381286-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | NSUN2, UPF1, SNRPE | CHRM2 4848/4885CHRM4 4804/4885CHRM5 4787/4885 |
| US-20160046662-A1 | OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES | EEA1, RNASE1, ASGR1 | CHRM2 4777/4885CHRM4 4541/4885CHRM5 4816/4885 |
| US-20160339107-A1 | OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES | EEA1, RNASE1, ASGR1 | CHRM2 4777/4885CHRM4 4541/4885CHRM5 4816/4885 |
| US-20260048135-A1 | COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | MYLK2, PRKCG, PRKAG2 | CHRM2 3892/4885CHRM4 4192/4885CHRM5 3877/4885 |
| US-20250381285-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | TNNC1, PYGM, MYOF | CHRM2 2268/4885CHRM4 3113/4885CHRM5 2993/4885 |
| US-12491257-B2 | Compositions and methods of using PRKAG2-targeting antibody-oligonucleotide conjugates | PRKCG, PRKAG2, PRKAG1 | CHRM2 3492/4885CHRM4 3944/4885CHRM5 3682/4885 |
| US-20260007766-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | MYOF, MTPN, TTN | CHRM2 3069/4885CHRM4 3565/4885CHRM5 3442/4885 |
| US-20130131155-A1 | Optimized In Vivo Delivery System with Endosomolytic Agents for Nucleic Acid Conjugates | EEA1, RNASE1, ASGR1 | CHRM2 4777/4885CHRM4 4541/4885CHRM5 4816/4885 |
| US-20250352651-A1 | COMPOSITIONS COMPRISING PLN-TARGETING ANTI-TRANSFERRIN RECEPTOR ANTIBODY-POLYNUCLEOTIDES AND METHODS OF USE THEREOF TO TREAT CARDIOMYOPATHY | TNNC1, TNNI3, TFRC | CHRM2 4485/4885CHRM4 4272/4885CHRM5 3836/4885 |
| US-20260014266-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | TNNC1, MYOF, MYH2 | CHRM2 2388/4885CHRM4 3970/4885CHRM5 4319/4885 |
| US-12486328-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | MYOF, MTPN, PYGM | CHRM2 3349/4885CHRM4 3301/4885CHRM5 3434/4885 |
| US-12529056-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | UPF1, MYOF, MTPN | CHRM2 2998/4885CHRM4 2801/4885CHRM5 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.